Literature DB >> 2985058

Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

T W Doebber, M S Wu, J C Robbins, B M Choy, M N Chang, T Y Shen.   

Abstract

Evidence from three types of experiments indicates that platelet activating factor (PAF)1 is an important mediator of endotoxin-induced hypotension in rats. a) Endotoxin infusion stimulates the time-dependent appearance of PAF in the blood. b) PAF infusion results immediately (less than 30 sec) in hypotension while endotoxin-induced hypotension takes 3-5 min to occur, allowing time for PAF production. c) Infusion of the specific PAF-receptor antagonist kadsurenone (2.2 mumole/kg bolus, 0.9 mumoles/min/kg continuous infusion), which inhibits PAF-induced hypotension by 67%, causes a 67% reversal of endotoxin-elicited hypotension. An additional finding of this study is that rats respond hypotensively to each of a series of low-dose PAF infusions but only to the first low-dose endotoxin infusion. These endotoxin-refractory rats do respond to subsequent PAF infusions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985058     DOI: 10.1016/s0006-291x(85)80014-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  57 in total

1.  Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli.

Authors:  L Molina; S Studenberg; G Wolberg; W Kazmierski; J Wilson; A Tadepalli; A C Chang; S Kosanke; L Hinshaw
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Induction of platelet-activating factor in mice by intravenous administration of a neutral fraction of bakers' yeast mannan.

Authors:  T Mikami; K Fukushi; M Ishitani; K Ishitani; S Suzuki; M Suzuki
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Kinetic studies of human and rat neutrophil lysoPAF acetyltransferase using lysoPAF and dansyllysoPAF as substrates.

Authors:  P W Schindler; E Ninio
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 4.  Cardiovascular effects of platelet-activating factor.

Authors:  R E Goldstein; G Z Feuerstein; L M Bradley; J J Stambouly; F R Laurindo; N J Davenport
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.

Authors:  J Sörensen; B Kald; C Tagesson; M Lindahl
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

6.  Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Authors:  M Giral; D Balsa; R Ferrando; M Merlos; J Garcia-Rafanell; J Forn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking.

Authors:  T Imaizumi
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

8.  Inhibition of endotoxin-induced bacterial translocation in mice.

Authors:  E A Deitch; L Ma; W J Ma; M B Grisham; D N Granger; R D Specian; R D Berg
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

9.  Protection of platelet-activating factor-induced acute renal failure by BN 52021.

Authors:  E Pirotzky; P Colliez; C Guilmard; J Schaeverbeke; J M Mencia-Huerta; P Braquet
Journal:  Br J Exp Pathol       Date:  1988-04

10.  Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat.

Authors:  J G Filep; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.